T1	Participants 106 133	patients with liver failure
T2	Participants 517 601	146 patients with liver failure and prothrombin time activity percentage (PTA) â‰¤ 40%
T3	Participants 639 728	92 MARS treatment sessions in the heparin-free group and 82 in the low-dose heparin group
